• About Us
  • Contact Us
Cure IBM
  • Home
  • IBM FAQ
  • Diagnosis
    • Introduction
    • Symptoms
    • Examination
    • Blood Tests
    • Electromyogram (EMG) and Nerve Conduction Studies
    • Magnetic Resonance Imaging (MRI)
    • Muscle Biopsy
    • Misdiagnosis
  • Treatment
    • Introduction
    • Medications
    • Clinical Trials
    • Exercise
    • Nutrition and Weight Control
    • Falls
    • Swallowing
    • Psychology
  • Resources
    • Links
    • Glossary
  • IBM Blog
  • Donate
Menu
AAVogen Seeks Investment Funding for Development of New Therapy to Treat Inclusion Body Myositis

AAVogen Seeks Investment Funding for Development of New Therapy to Treat Inclusion Body Myositis

by Kevin Dooley, MD | Mar 19, 2020 | News and Information

AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from...
$102,340 Grant Awarded for Inclusion Body Myositis Research

$102,340 Grant Awarded for Inclusion Body Myositis Research

by Kevin Dooley, MD | Feb 5, 2020 | News and Information

The 2019 Million Dollar Bike Ride grant of $102,340 for inclusion body myositis (IBM) research has been awarded to Dr. Steven A. Greenberg of Brigham and Women’s Hospital and Harvard Medical School. Dr. Greenberg will study, “Development of a Chemokine Targeted...
New Research Regarding Hand Function in Inclusion Body Myositis

New Research Regarding Hand Function in Inclusion Body Myositis

by Kevin Dooley, MD | Jan 29, 2020 | News and Information

A recently published study finds that the Inclusion Body Myositis Functional Rating Scale (IBMFRS) does not correlate as well as expected with measures of grip strength and finger flexor strength. This suggests that the IBMFRS could be improved to more accurately...
Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis

by Kevin Dooley, MD | Dec 18, 2019 | News and Information

Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA...
Coach Randy Marks Thrives Despite Inclusion Body Myositis

Coach Randy Marks Thrives Despite Inclusion Body Myositis

by Kevin Dooley, MD | Jun 20, 2019 | News and Information

Hall of Fame Night Randy Marks, who coached Villanova’s lacrosse team for 24 years, had the enormous pleasure of introducing his son, Brian, as he was inducted into the Villanova Athletics Hall of Fame last February. A former star athlete himself, Coach Marks was...
« Older Entries
Next Entries »

Recent Posts

  • $68,245 Grant Available for Study of Inclusion Body Myositis
  • You can Bike, Walk, Run, or Ride for IBM on Saturday, June 13!
  • The Million Dollar Bike Ride Needs YOUR Help!
  • Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic
  • Caution Regarding the Use of Chloroquine to Treat Coronavirus in Myositis Patients

Archives

  • August 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017

Tags

accessible home advocacy arimoclomol asking for help autophagy awareness bimagrumab clinical trial clinical trials coping coronavirus exercise exoskeleton fundraising IBMFRS IB Myositis Inclusion Body Myositis Functional Rating Scale Jerry King Joe Sanchez kitchen laundry Living with IBM Martin Jarry MDBR Million Dollar Bike Ride mTOR myostatin patient story Patrick Warner personal story physical therapist physical therapy physiotherapist physiotherapy positive attitude psychology quality of life rapamycin Rare Disease Day research shoes support groups towel walking Yale IBM Registry
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Facebook
  • Twitter

© 2021 Cure IBM | Website design and digital media services by Abaton Consulting

This website uses cookies to enhance user experience. By using our website, you agree to our Privacy Policy. Got it!